Psychedelic Weekly Headlines | June 24th

June 24, 2022

Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.


Performance of psychedelic public companies this past week.

Company News

Numinus Wellness ($NUMI | $NUMIF) launched a Utah-based pilot program to help businesses improve employee mental health by offering ketamine-assisted psychotherapy and announced that their subsidiary, Numinus Bioscience, filed a patent application for a rapid production process for Psilocybe and fungi species containing psilocybin and other compounds. Details

Nirvana Life Science ($NIRV) filed a patent application for a novel process for the isolation of a psychedelic 4-PO-Psilocin compound. The process is expected to significantly increase the efficacy and safety in administering psychedelic compounds in clinical settings. Press Release

Mindset Pharma ($MSET | $MSSTF) entered into an innovative research collaboration with the Centre for Addiction and Mental Health to sponsor a preclinical study of their novel and patented second generation psilocybin-like compound, MSP-1014. Press Release

Ceruvia Lifesciences (Private) submitted an IND application to begin a Phase I dose study to assess the safety and tolerability of NYPRG-101, a non-hallucinogenic analog of LSD being developed as a potential treatment for migraines. Press Release

Optimi Health ($OPTI | $OPTHF) submitted a request with Health Canada for an amendment to their Controlled Substances Dealer’s Licence. The amendment would enable Optimi Health to synthesize MDMA and other synthetic psychedelics. Press Release

Tryp Therapeutics ($TRYP | $TRYPF) appointed Sid Taubenfeld as Chief Operating Officer to further expand patient access to psilocybin-based treatments. Taubenfeld is a seasoned executive with healthcare and biotech expertise. Press Release


Psychedelic Finance: Interview with Alan K Davis of Center for Psychedelic Drug Research and Education

Rolling Stone: How an NHL Enforcer Broke His Body — and Turned to Psychedelics to Heal His Brain

SF Standard: UCSF Kicks Off First-Ever Trial of Psilocin

NY Times: After Six-Decades, Psychedelic Therapy Returns to the V.A.

KPMG: Psychedelic Drugs: A Market Poised for Takeoff

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.